Cerevast Therapeutics, Inc.
Cerevast Medical is a late-stage medical technology company focused on developing innovative treatments for neurologic disorders, including stroke rehabilitation and acute ischemic stroke. The company licenses advanced ultrasound and neuromodulation technologies, collaborates on clinical trials, and aims to improve patient outcomes through non-invasive therapies.
Industries
Nr. of Employees
small (1-50)
Cerevast Therapeutics, Inc.
Products
Portable transcranial ultrasound therapy system for acute ischemic stroke
A non-invasive system comprising an ultrasonic head-frame to position transducers and a control unit to deliver therapeutic ultrasound signals intended to be used adjunctively with systemic thrombolytics to enhance clot dissolution and recanalization.
Ocular ultrasound therapy combined with intravenous microbubble agent for retinal vein occlusion
A non-invasive ocular therapy that pairs intravenous microbubble contrast agents with ultrasound delivered across the closed eyelid to target and improve blood flow in occluded retinal veins.
Transcranial ultrasound neuromodulation system for post-stroke rehabilitation
Devices that transmit focused ultrasonic energy to motor cortex regions to increase neuroplasticity and support rehabilitation when used alongside traditional physical therapy.
Portable transcranial ultrasound therapy system for acute ischemic stroke
A non-invasive system comprising an ultrasonic head-frame to position transducers and a control unit to deliver therapeutic ultrasound signals intended to be used adjunctively with systemic thrombolytics to enhance clot dissolution and recanalization.
Ocular ultrasound therapy combined with intravenous microbubble agent for retinal vein occlusion
A non-invasive ocular therapy that pairs intravenous microbubble contrast agents with ultrasound delivered across the closed eyelid to target and improve blood flow in occluded retinal veins.
Transcranial ultrasound neuromodulation system for post-stroke rehabilitation
Devices that transmit focused ultrasonic energy to motor cortex regions to increase neuroplasticity and support rehabilitation when used alongside traditional physical therapy.
Services
Sponsor and operational oversight for multi-center clinical studies of ultrasound-based therapies, including phase progression and incorporation of prior trial learnings.
On-site training and education for hospital and emergency staff on safe placement and operation of portable therapeutic ultrasound head-frames and control units.
Licensing of university-originated ultrasound neuromodulation technologies and management of patent assets to support device development.
Sponsor and operational oversight for multi-center clinical studies of ultrasound-based therapies, including phase progression and incorporation of prior trial learnings.
On-site training and education for hospital and emergency staff on safe placement and operation of portable therapeutic ultrasound head-frames and control units.
Licensing of university-originated ultrasound neuromodulation technologies and management of patent assets to support device development.
Expertise Areas
- Transcranial ultrasound therapy development
- Sonothrombolysis clinical research
- Ultrasound neuromodulation for neurorehabilitation
- Ocular ultrasound therapy combined with microbubbles
Key Technologies
- Transcranial ultrasound
- Ultrasound-enhanced thrombolysis (sonothrombolysis)
- Ultrasound neuromodulation
- Microbubble-mediated ultrasound therapy
News & Updates
Baptist Hospital Chosen for Stroke Study
Baptist Hospital in Beaumont, Texas, is the initial site for a clinical study involving the Aureva Pulse device to treat stroke patients, with potential global implications.
Cerevast Licenses Ultrasound Technologies from ASU
Cerevast licensed ultrasound neuromodulation technologies from Arizona State University for post-stroke rehabilitation, enhancing its portfolio of non-invasive therapies.
Cerevast Enters Collaboration with Lantheus for RVO Treatment
A development and supply agreement with Lantheus to use microbubbles with Cerevast’s ultrasound device for retinal vein occlusion treatment.
CLOTBUST-ER Trial Results Published
The first phase 3 trial assessing sonothrombolysis in stroke was published in Lancet Neurology, highlighting the promise and challenges of ultrasound-assisted clot dissolution.
Analysis of Equipoise Shift in CLOTBUST-ER
A study published in Therapeutic Advances discusses the impact of increased endovascular therapy on clinical trials for sonothrombolysis.
Sonothrombolysis in Patients With Acute Ischemic Stroke: Meta-Analysis
A meta-analysis published in AJH shows that sonothrombolysis nearly doubles the odds of recanalization in large vessel occlusion strokes.
Baptist Hospital Chosen for Stroke Study
Baptist Hospital in Beaumont, Texas, is the initial site for a clinical study involving the Aureva Pulse device to treat stroke patients, with potential global implications.
Cerevast Licenses Ultrasound Technologies from ASU
Cerevast licensed ultrasound neuromodulation technologies from Arizona State University for post-stroke rehabilitation, enhancing its portfolio of non-invasive therapies.
Cerevast Enters Collaboration with Lantheus for RVO Treatment
A development and supply agreement with Lantheus to use microbubbles with Cerevast’s ultrasound device for retinal vein occlusion treatment.
CLOTBUST-ER Trial Results Published
The first phase 3 trial assessing sonothrombolysis in stroke was published in Lancet Neurology, highlighting the promise and challenges of ultrasound-assisted clot dissolution.
Analysis of Equipoise Shift in CLOTBUST-ER
A study published in Therapeutic Advances discusses the impact of increased endovascular therapy on clinical trials for sonothrombolysis.
Sonothrombolysis in Patients With Acute Ischemic Stroke: Meta-Analysis
A meta-analysis published in AJH shows that sonothrombolysis nearly doubles the odds of recanalization in large vessel occlusion strokes.